Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 196

1.

Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.

Agudo-López A, Prieto-García E, Alemán J, Pérez C, Díaz-García CV, Parrilla-Rubio L, Cabrera S, Navarro-Ranninger C, Cortés-Funes H, López-Martín JA, Agulló-Ortuño MT.

Mol Cancer. 2017 Feb 23;16(1):45. doi: 10.1186/s12943-017-0618-7.

2.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I, Olier C, Fernández-Aramburo A, Llorca C, González X, Llorente R, Torregrosa D, Álvarez I, Gálve E, Bueno C, Garau I, García MJ, González-Santiago S, Ballesteros AI, Blanco E, Galán A, González S, Perelló A, Cortés-Funes H, Grávalos C.

Anticancer Res. 2015 Dec;35(12):6941-50.

PMID:
26637920
3.

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J.

Eur J Cancer. 2015 Aug;51(12):1481-9. doi: 10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11.

PMID:
26074397
4.

Risk factors associated with Clostridium difficile infection in adult oncology patients.

Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-Miguel MÁ, Díaz-García CV, Cortijo-Cascajares S, Cortes-Funes H, Agulló-Ortuño MT.

Support Care Cancer. 2015 Jun;23(6):1569-77. doi: 10.1007/s00520-014-2506-7. Epub 2014 Nov 20.

PMID:
25410088
5.

Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

Díaz-García CV, Agudo-López A, Pérez C, Prieto-García E, Iglesias L, Ponce S, Rodríguez Garzotto A, Rodríguez-Peralto JL, Cortés-Funes H, López-Martín JA, Agulló-Ortuño MT.

Tumour Biol. 2015 Feb;36(2):1199-206. doi: 10.1007/s13277-014-2729-8. Epub 2014 Oct 25.

PMID:
25344212
6.

Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.

García-Escobar I, Parrilla L, Ortega LM, Castellanos D, Pallarés MA, Cortés-Funés H.

Mol Clin Oncol. 2014 Nov;2(6):923-926. Epub 2014 Jul 29.

7.

Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Agulló-Ortuño MT, Díaz-García CV, Agudo-López A, Pérez C, Cortijo A, Paz-Ares L, López-Ríos F, Pozo F, de Castro J, Cortés-Funes H, López Martín JA.

J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53. doi: 10.1007/s00432-014-1787-z. Epub 2014 Aug 1.

PMID:
25081930
8.

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J.

Breast. 2014 Oct;23(5):656-62. doi: 10.1016/j.breast.2014.06.017. Epub 2014 Jul 19.

PMID:
25047747
9.

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.

Rodriguez Garzotto A, Cortijo Casacajares S, Pernaut C, Ruiz Ares GJ, Otero Blas I, Heine O, Turner M, Rebollo Laserna F, Cortes Funes H, Lorenz A.

J Blood Med. 2014 Apr 28;5:43-8. doi: 10.2147/JBM.S57887. eCollection 2014. Erratum in: J Blood Med. 2014;5:129. Cortijo Casacajares, Susana [added]; Pernaut, Cristina [added]; Ruiz Ares, Gustavo Javier [added]; Otero Blas, Irene [added]; Cortes Funes, Hernan [added].

10.

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Muñoz C, Vega E, Calderón MJ, Sancho B, Cortes-Funes H.

Breast. 2014 Jun;23(3):201-8. doi: 10.1016/j.breast.2014.01.016. Epub 2014 Mar 1. Review.

11.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2014 Jan;25(1):216-25. doi: 10.1093/annonc/mdt461. Epub 2013 Nov 19.

PMID:
24256848
12.

Chemotherapy for cholangiocarcinoma: An update.

Ramírez-Merino N, Aix SP, Cortés-Funes H.

World J Gastrointest Oncol. 2013 Jul 15;5(7):171-6. doi: 10.4251/wjgo.v5.i7.171.

13.

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

Ciruelos E, Cortes-Funes H, Ghanem I, Manso L, Arteaga C.

Anticancer Drugs. 2013 Sep;24(8):769-80. doi: 10.1097/CAD.0b013e328363adc5. Review.

PMID:
23838677
14.

Guidelines for the management of breakthrough pain in patients with cancer.

Caraceni A, Davies A, Poulain P, Cortés-Funes H, Panchal SJ, Fanelli G.

J Natl Compr Canc Netw. 2013 Mar;11 Suppl 1:S29-36.

PMID:
23520183
15.

Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.

Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C, Tabernero J, Coronado C, García M, Soto Matos-Pita A, Miguel-Lillo B, Cullell-Young M, Iglesias Dios JL, Paz-Ares L.

Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83. doi: 10.1007/s00280-013-2170-5. Epub 2013 May 5.

PMID:
23645288
16.

DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.

Díaz-García CV, Agudo-López A, Pérez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J, Cortijo A, Martínez-Villanueva M, Iglesias L, García-Carbonero R, Fresno Vara JA, Gámez-Pozo A, Palacios J, Cortés-Funes H, Paz-Ares L, Agulló-Ortuño MT.

Carcinogenesis. 2013 May;34(5):1031-8. doi: 10.1093/carcin/bgt022. Epub 2013 Jan 24.

PMID:
23349018
17.

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, Vega E, Manneh R, Dorta M, Cortés-Funes H.

Clin Transl Oncol. 2013 Jun;15(6):467-71. doi: 10.1007/s12094-012-0954-4. Epub 2012 Dec 21.

PMID:
23263907
18.

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.

Gravalos C, Salut A, García-Girón C, García-Carbonero R, León AI, Sevilla I, Maurel J, Esteban B, García-Rico E, Murias A, Cortés-Funes H.

Clin Transl Oncol. 2012 Aug;14(8):606-12. doi: 10.1007/s12094-012-0843-x. Epub 2012 Jul 19.

19.

Behaviour of breast cancer molecular subtypes through tumour progression.

Castaneda CA, Andrés E, Barcena C, Gómez HL, Cortés-Funés H, Ciruelos E.

Clin Transl Oncol. 2012 Jun;14(6):481-5. doi: 10.1007/s12094-012-0827-x.

PMID:
22634538
20.

Biological markers of cisplatin resistance in advanced testicular germ cell tumours.

García-Velasco A, Durán I, García E, Tarón M, Ballestín C, Castellanos D, Cortés-Funés H, Paz-Ares L.

Clin Transl Oncol. 2012 Jun;14(6):452-7. doi: 10.1007/s12094-012-0823-1.

PMID:
22634534

Supplemental Content

Loading ...
Support Center